Formoterol dry-powder inhaler for the treatment of asthma and chronic obstructive pulmonary disease

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 17, 2007, Pages 3069-3084

  Prenner, Bruce M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adrenergic agonist; Albuterol; Anticholinergic; Asthma; Bronchospasm; COPD; Exercise; Formoterol; Ipratropium; Salmeterol; Tiotropium

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; EASYHALER; FORMOTEROL; FORMOTEROL FUMARATE; GLUCOSE; IPRATROPIUM BROMIDE; NEDOCROMIL; OXEZ; OXEZE; PLACEBO; POTASSIUM; SALBUTAMOL; SALMETEROL; STEROID; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ARTICLE; ASTHMA; BRONCHITIS; BRONCHODILATING ACTIVITY; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER; EXERCISE; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOTENSION; LOOSE FECES; LOW DRUG DOSE; LUNG FUNCTION TEST; MAINTENANCE THERAPY; METABOLIC DISORDER; METERED DOSE INHALER; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; MONOTHERAPY; MULTIPLE DRUG DOSE; NERVOUSNESS; NONHUMAN; PHARYNGITIS; POTASSIUM BLOOD LEVEL; POWDER INHALER; QT INTERVAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; TREATMENT DURATION; TREMOR; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ANIMALS; ASTHMA; BRONCHODILATOR AGENTS; EQUIPMENT DESIGN; ETHANOLAMINES; HUMANS; NEBULIZERS AND VAPORIZERS; POWDERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ADRENERGIC, BETA-2; TREATMENT OUTCOME;

EID: 37349087502     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.17.3069     Document Type: Article

References (54)

1. SEARS MR: The evolution of β2-agonists. Respir. Med. (2001) 95(Suppl. B):S2-S6.
2. RABE KF, HURD S, ANZUETO A et al.: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. (2007) 176(6):532-555.
3. LEMOINE H, OVERLACK C, KOHL A, WORTH H, REINHARDT D: Formoterol, fenoterol, and salbutamol as partial agonists for relaxation of maximally contracted guinea pig tracheae: comparison of relaxation with receptor binding. Lung (1992) 170(3)163-180.
4. LOTVALL J: Pharmacological similarities and differences between β2-agonists. Respir. Med. (2001) 95(Suppl. B):S7-S11.
5. ANDERSON GP: Long acting inhaled β-adrenoceptor agonists the comparative pharmacology of formoterol and salmeterol. Agent Action Suppl. (1993) 43:253-269.
6. ANDERSON GP: Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci. (1993) 52(26):2145-2160.
7. VAN DER WOUDE HJ, AALBERS R: Long-acting β2-agonists: comparative pharmacology and clinical outcomes. Am. J. Respir. Med. (2002) 1(1):55-74.
8. Foradil® Aerolizer® (formoterol fumarate inhalation powder). Full Prescribing Information, Schering Corporation, Kenilworth, NJ (2006).
9. Foradil® Certihaler® (formoterol fumarate inhalation powder). Full Prescribing Information, Novartis Pharmaceuticals Corporation, East Hanover, NJ (2006).
10. LECAILLON JB, KAISER G, PALMISANO M, MORGAN J, DELLA CIOPPA G: Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. Eur. J. Clin. Pharmacol. (1999) 55(2):131-138.
11. MARZO A, MONTI NC, TETTAMANTI RA et al.: Bioequivalence of inhaled formoterol fumarate assessed from pharmacodynamic, safety and urinary pharmacokinetic data. Arzneimittelforschung (2000) 50(6):559-563.
12. PAUWELS RA, SEARS MR, CAMPBELL M et al.: Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur. Respir. J. (2003) 22(5):787-794.
13. TATTERSFIELD AE, LOFDAHL CG, POSTMA DS et al.: Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet (2001) 357(9252):257-261.
14. BOONSAWAT W, CHAROENRATANAKUL S, POTHIRAT C et al.: Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir. Med. (2003) 97(9):1067-1074.
15. BENSCH G, LAPIDUS RJ, LEVINE BE et al.: A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann. Allergy Asthma Immunol. (2001) 86(1):19-27.
16. BUSSE W, LEVINE B, ANDRIANO K, LAVECCHIA C, YEGEN U: Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study. Clin. Ther. (2004) 26(10):1587-1598.
17. LAFORCE C, PRENNER BM, ANDRIANO K, LAVECCHIA C, YEGEN U: Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma. J. Asthma (2005) 42(2):101-106.
18. MOLIMARD M, BOURCEREAU J, LE GROS V et al.: Comparison between formoterol 12 mg b.i.d. and on-demand salbutamol in moderate persistent asthma. Respir. Med. (2001) 95(1):64-70.
19. PLESKOW W, LAFORCE CF, YEGEN U, MATOS D, DELLA CIOPPA G: Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial. J. Asthma (2003) 40(5):505-514.
20. MITCHELL C, JENKINS C, SCICCHITANO R, RUBINFELD A, KOTTAKIS J: Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. Pulm. Pharmacol. Ther. (2003) 16(5):299-306.
21. CHUCHALIN AG, SVENSSON K, STAHL E et al.: A health-related quality-of-life comparison of formoterol (Oxis) Turbuhaler plus budesonide (Pulmicort) Turbuhaler with budesonide Turbuhaler alone and noncorticosteroid treatment in asthma: a randomized clinical study in Russia. Respiration (2002) 69(5):427-433.
22. BRAMBILLA C, LE GROS V, BOURDEIX I: Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study. Clin. Ther. (2003) 25(7):2022-2036.
23. DAHL R, CREEMERS JP, VAN NOORD J et al.: Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma. Respiration (2004) 71(2):126-133.
24. DUBAKIENE R, NARGELA R, SAKALAUSKAS R et al.: Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer. Respiration (2006) 73(4):441-448.
25. CONDEMI JJ: Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial. Clin. Ther. (2001) 23(9)1529-1541.
26. SELROOS O, EKSTROM T: Formoterol Turbuhaler 4.5 mg (delivered dose) has a rapid onset and 12-h duration of bronchodilation. Pulm. Pharmacol. Ther. (2002) 15(2):175-183.
27. SHAPIRO GS, YEGEN U, XIANG J, KOTTAKIS J, DELLA CIOPPA G: A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol. Clin. Ther. (2002) 24(12):2077-2087.
28. BENHAMOU D, CUVELIER A, MUIR JF et al.: Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir. Med. (2001) 95(10):817-821.
29. NI CHROININ M, GREENSTONE IR, DANISH A et al.: Long-acting β32-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst. Rev. (2005) (4):CD005535.
30. BENSCH G, BERGER WE, BLOKHIN BM et al.: One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann. Allergy Asthma Immunol. (2002) 89(2):180-190.
31. BRONSKY EA, YEGEN U, YEH CM, LARSEN LV, DELLA CIOPPA G: Formoterol provides long-lasting protection against exercise-induced bronchospasm. Ann. Allergy Asthma Immunol. (2002) 89(4):407-412.
32. HERMANSEN MN, NIELSEN KG, BUCHVALD F et al.: Acute relief of exercise-induced bronchoconstriction by inhaled formoterol in children with persistent asthma. Chest (2006) 129(5):1203-1209.
33. PEARLMAN D, MILGROM H, TILL D, ZIEHMER B: Effect of formoterol fumarate treatment on exercise-induced bronchoconstriction in children. Ann. Allergy Asthma Immunol. (2006) 97(3):382-388.
34. KOTTAKIS J, CIOPPA GD, CREEMERS J et al.: Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can. Respir. J. (2002) 9(2):107-115.
35. RICHTER K, STENGLEIN S, MUCKE M et al.: Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration (2006) 73(4):414-419.
36. DAHL R, GREEFHORST LA, NOWAK D et al.: Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2001) 164(5):778-784.
37. ROSSI A, KRISTUFEK P, LEVINE BE et al.: Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest (2002) 121(4):1058-1069.
38. CAZZOLA M, DI MARCO F, SANTUS P et al.: The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm. Pharmacol. Ther. (2004) 17(1):35-39.
39. VAN NOORD JA, AUMANN JL, JANSSENS E et al.: Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. (2005) 26(2):214-222.
40. TASHKIN D, VARGHESE S: Formoterol plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD. 2007 AAAAI Annual Meeting. San Diego, CA (25 February 2007).
41. AALBERS R, AYRES J, BACKER V et al.: Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur. Respir. J. (2002) 19(5):936-943.
42. MEYER T, BRAND P, EHLICH H et al.: Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data. J. Aerosol. Med. (2004) 17(1):43-49.
43. BRONSKY EA, GROSSMAN J, HENIS MJ et al.: Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults. Curr. Med. Res. Opin. (2004) 20(2):131-137.
44. CHEW NY, CHAN HK: In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler. J. Aerosol. Med. (2001) 14(4):495-501.
45. CRIEE CP, MEYER T, PETRO W, SOMMERER K, ZEISING P: In vitro comparison of two delivery devices for administering formoterol: Foradil P and formoterol ratiopharm single-dose capsule inhaler. J. Aerosol. Med. (2006) 19(4):466-472.
46. GUHAN AR, COOPERS, OBORNE J et al.: Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax (2000) 55(8):650-656.
47. TASHKIN DP, COOPER CB: The role of long-acting bronchodilators in the management of stable COPD. Chest (2004) 125(1):249-259.
48. CAMPBELL SC, CRINER GJ, LEVINE BE et al.: Cardiac safety of formoterol 12mg twice daily in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. (2006).
49. KRUSE M, ROSENKRANZ B, DOBSON C, AYRE G, HOROWITZ A: Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma. Pulm. Pharmacol. Ther. (2005) 18(3):229-234.
50. ROSENKRANZ B, ROUZIER R, KRUSE M et al.: Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. Respir. Med. (2006) 100(4):666-672.
51. KAAE R, AGERTOFF L, PEDERSEN S et al.: Cumulative high doses of inhaled formoterol have less systemic effects in asthmatic children 6 - 11 years-old than cumulative high doses of inhaled terbutaline. Br. J. Clin. Pharmacol. (2004) 58(4):411-418.
52. POHUNEK P, MATULKA M, RYBNICEK O et al.: Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Pediatr. Allergy Immunol. (2004) 15(1):32-39.
53. LIPWORTH B, TAN S, DEVLIN M et al.: Effects of treatment with formoterol on bronchoprotection against methacholine. Am. J. Med. (1998) 104(5):431-438.
54. NELSON HS, WEISS ST, BLEECKER ER, YANCEY SW, DORINSKY PM: The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest (2006) 129(1):15-26.